Latest News

High adverse events with TB prevention in HIV-infected pregnant women


 

FROM CROI 2018


All women and their infants received the local standard of care for HIV. The investigators performed intensified TB case finding by using the WHO symptoms screening and exam, monitoring of signs and symptoms, conducting liver function tests, and screening for peripheral neuropathy.

“We had higher than expected adverse events in the study, but there was no statistical difference between arms,” she said.

In an intention-to-treat analysis, the rate of first maternal treatment-related grade 3 or greater adverse event or permanent drug discontinuation caused by toxicity (the primary endpoint) was 15.5% in the immediate IPT arm and 15.2% in the delayed IPT arm, a nonsignificant difference. The immediate therapy arm approached but did not quite reach the prespecified boundary of noninferiority, Dr. Gupta noted.

The per-protocol analysis of the primary endpoint was similar, at 17.6% vs. 17.8%, respectively.

Pages

Recommended Reading

Prenatal ART regimen with lowest risk is TDF-FTC-EFV
MDedge ObGyn
VIDEO: How to prevent, manage perinatal HIV infection
MDedge ObGyn
Herpes simplex type 2 infection markedly increases HIV risk
MDedge ObGyn
HIV antiretroviral resistance can affect more than 10% of pregnant women
MDedge ObGyn
Delayed HIV diagnoses still substantial for some at-risk groups
MDedge ObGyn
Teens with PID underscreened for HIV, syphilis
MDedge ObGyn
HHS creates new religious freedoms division
MDedge ObGyn
Trial seeks improved regimens for pregnant women with HIV
MDedge ObGyn
nPEP for HIV: Updated CDC guidelines available for primary care physicians
MDedge ObGyn
Efavirenz-based ART may hamper vaginal ring contraception
MDedge ObGyn